China Resources Sanjiu Medical & Pharmaceutical Co Ltd Cash Flow Reinvestment Rate
China Resources Sanjiu Medical & Pharmaceutical Co Ltd cash flow reinvestment rate. China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999) has a Cash Flow Reinvestment Rate of 0.56x as of December 2025, reinvesting CN¥1.45 Billion (capex CN¥545.33 Million plus investments CN¥-906.68 Million) from operating cash flow of CN¥2.60 Billion. See 000999 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of China Resources Sanjiu Medical & Pharmaceutical Co Ltd (1999–2025)
Cash flow reinvestment rate of China Resources Sanjiu Medical & Pharmaceutical Co Ltd from 1999 to 2025. Historical reinvestment intensity for China Resources Sanjiu Medical & Pharmaceutical Co Ltd across 26 annual periods. Explore China Resources Sanjiu Medical & Pharmac (000999) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
China Resources Sanjiu Medical & Pharmaceutical Co Ltd Cash Flow Reinvestment Rate by Year (1999–2025)
China Resources Sanjiu Medical & Pharmaceutical Co Ltd cash flow reinvestment rate by year from 1999 to 2025. Year-by-year capital reinvestment analysis for China Resources Sanjiu Medical & Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see how efficiently does China Resources Sanjiu Medical & Pharmac generate cash.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.45x | CN¥2.48 Billion | CN¥5.51 Billion | CN¥1.27 Billion | ▲ +91.1% |
| 2024 | 0.24x | CN¥1.04 Billion | CN¥4.40 Billion | CN¥790.07 Million | ▼ -40.3% |
| 2023 | 0.39x | CN¥1.65 Billion | CN¥4.19 Billion | CN¥857.21 Million | ▼ -65.5% |
| 2022 | 1.14x | CN¥3.43 Billion | CN¥3.01 Billion | CN¥951.57 Million | ▲ +23.5% |
| 2021 | 0.92x | CN¥1.74 Billion | CN¥1.88 Billion | CN¥870.80 Million | ▲ +46.3% |
| 2020 | 0.63x | CN¥1.40 Billion | CN¥2.22 Billion | CN¥621.82 Million | ▲ +89.3% |
| 2019 | 0.33x | CN¥657.49 Million | CN¥1.97 Billion | CN¥535.97 Million | ▼ -22.3% |
| 2018 | 0.43x | CN¥820.07 Million | CN¥1.91 Billion | CN¥600.36 Million | ▼ -11.5% |
| 2017 | 0.48x | CN¥774.84 Million | CN¥1.60 Billion | CN¥374.74 Million | ▼ -57.3% |
| 2016 | 1.13x | CN¥1.58 Billion | CN¥1.39 Billion | CN¥354.33 Million | ▲ +58.3% |
| 2015 | 0.72x | CN¥902.16 Million | CN¥1.26 Billion | CN¥330.65 Million | ▲ +148.6% |
| 2014 | 0.29x | CN¥341.22 Million | CN¥1.18 Billion | CN¥341.22 Million | ▲ +19.1% |
| 2013 | 0.24x | CN¥354.89 Million | CN¥1.47 Billion | CN¥354.89 Million | ▼ -41.9% |
| 2012 | 0.42x | CN¥504.52 Million | CN¥1.21 Billion | CN¥504.52 Million | ▼ -3.0% |
| 2011 | 0.43x | CN¥409.79 Million | CN¥954.90 Million | CN¥409.79 Million | ▲ +34.8% |
| 2010 | 0.32x | CN¥270.00 Million | CN¥848.28 Million | CN¥270.00 Million | ▲ +41.1% |
| 2009 | 0.23x | CN¥192.93 Million | CN¥855.05 Million | CN¥192.93 Million | ▼ -79.1% |
| 2008 | 1.08x | CN¥1.20 Billion | CN¥1.12 Billion | CN¥1.20 Billion | ▲ +187.7% |
| 2007 | 0.37x | CN¥226.78 Million | CN¥605.30 Million | CN¥226.78 Million | ▲ +17.4% |
| 2006 | 0.32x | CN¥135.81 Million | CN¥425.51 Million | CN¥135.81 Million | ▼ -80.4% |
| 2005 | 1.63x | CN¥37.14 Million | CN¥22.83 Million | CN¥37.14 Million | ▼ -66.4% |
| 2003 | 4.84x | CN¥135.88 Million | CN¥28.09 Million | CN¥135.88 Million | ▲ +1289.6% |
| 2002 | 0.35x | CN¥172.67 Million | CN¥496.12 Million | CN¥172.67 Million | ▼ -55.1% |
| 2001 | 0.77x | CN¥118.83 Million | CN¥153.44 Million | CN¥118.83 Million | ▲ +21.2% |
| 2000 | 0.64x | CN¥170.58 Million | CN¥266.86 Million | CN¥170.58 Million | ▲ +5.0% |
| 1999 | 0.61x | CN¥73.43 Million | CN¥120.63 Million | CN¥73.43 Million | — |